Asset
Rebisufligene Etisparvovec
Ultragenyx Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02716246 | phase2_3 | recruiting | 2016-04-25 | 2029-03-01 | Ultragenyx Pharmaceutical Inc | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH |
FDA applications (0)
This company has no applications containing this asset.